Plasma asymmetric dimethylarginine (ADMA) concentrations in patients with first and multiple episode schizophrenia

Psychiatry Research

Volumn 190, Issue 2-3, 2011, Pages 177-180

  Celik, Cemil ^a   Cayci, Tuncer ^a   Ozdemir, Barbaros ^a   Akgul, Emin Ozgur ^a   Zincir, Serkan ^a   Balikci, Adem ^a   Uzun, Ozcan ^a   Yaman, Halil ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

ADMA; Schizophrenia; Schizophrenia type

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS;

ADULT; ARGININE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 82955187711     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.06.003     Document Type: Article

References (38)

1. Andreasen N.C. Methods for assessing positive and negative symptoms. Modern Problems of Pharmacopsychiatry 1990, 24:73-88.
2. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Archives of General Psychiatry 1992, 49:943-958.
3. Bełtowski J., Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Reports 2006, 58:159-178.
4. Böger R.H., Bode-Böger S.M., Tsao P.S., Lin P.S., Chan J.R., Cooke J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. Journal of the American College of Cardiology 2000, 36:2287-2295.
5. Brambilla P., Cerini R., Fabene P.F., Andreone N., Rambaldelli G., Farace P., Versace A., Perlini C., Pelizza L., Gasparini A., Gatti R., Bellani M., Dusi N., Barbui C., Nosè M., Tournikioti K., Sbarbati A., Tansella M. Assessment of cerebral blood volume in schizophrenia: a magnetic resonance imaging study. Journal of Psychiatric Research. 2007, 41:502-510.
6. Brown S., Inskip H., Barraclough B. Causes of excess mortality of schizophrenia. The British Journal of Psychiatry 2000, 177:212-217.
7. Casey D.E., Hansen T.E. Excessive morbidity and mortality in schizophrenia. Medical Illness and Schizophrenia 2003, American Psychiatric Publishing, Washington (DC). J.M. Meyer, H.A. Nasrallah (Eds.).
8. Chan N.N., Chan J.C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 2002, 45:1609-1616.
9. Chen B.M., Xia L.W., Zhao R.Q. Determination of NG, NG-dimethylarginine in human plasma by high-performance liquid chromatography. Journal of Chromatography B, Biomedical Sciences and Applications 1997, 692:467-471.
10. Das I., Khan N.S., Puri B.K., Hirsch S.R. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neuroscience Letters 1996, 215:209-211.
11. De Hert M., Schreurs V., Vancampfort D., Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009, 8:15-22.
12. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. The American Journal of Psychiatry 2008, 165:1015-1023.
13. Erkoc S., Arkonac O., Atakli C., Ozmen E. Negatif semptomlari degerlendirme olceginin guvenilirligi ve gecerliligi. Dusunen Adam. 1991, 4:16-19.
14. Erkoc S., Arkonac O., Atakli C., Ozmen E. Pozitif Semptomlari Degerlendirme Olceginin guvenilirligi ve gecerliligi. Dusunen Adam. 1991, 4:20-24.
15. Faraci F.M., Brian J.E. Nitric oxide and the cerebral circulation. Stroke 1994, 25:692-703.
16. Faraci F.M., Brian J.E., Heistad D.D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. American Journal of Physiology 1995, 269:1522-1527.
17. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinical Version 1997, American Psychiatric Press, Inc, Washington D.C.
18. Gonul A.S., Kula M., Esel E., Tutus A., Tutus A., Sofuoglu S.A. Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Research: Neuroimaging 2003, 123:199-205.
19. Gur R.E., Skolnick B.E., Gur R.C., Caroff S., Rieger W., Obrist W.D., Resnick S., Reivich M. Brain function in psychiatric disorders. Regional cerebral blood flow in medicated schizophrenics. Archives of General Psychiatry 1983, 40:1250-1254.
20. Harris E.C., Barraclough B. Excess mortality of mental disorder. The British Journal of Psychiatry 1998, 173:11-53.
21. Heiskanen T., Niskanen L., Lyytikäinen R., Saarinen P.I., Hintikka J. Metabolic syndrome in patients with schizophrenia. The Journal of Clinical Psychiatry 2003, 64:575-579.
22. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 2005, 150:1115-1121.
23. Iwahashi K., Yoneyama H., Ohnishi T., Nakamura K., Miyatake R., Suwaki H., Hosokawa K., Ichikawa Y. Haloperidol inhibits neuronal nitric oxide synthase activity by preventing electron transfer. Neuropsychobiology 1996, 33:76-79.
24. Lukoff D., Nuechhtriein K.H., Vertura J. Brief Psychiatric Rating Scale (BPRS) Version 3.0, Expanded Version 1993, UCLA Department of Psychiatry and Biobehaviioral Sciences, West Los Angeeles Medical Center, Los Angeles.
25. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. Journal of the American College of Cardiology 2001, 38:111-116.
26. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., Whitley G.S., Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. British Journal of Pharmacology 1996, 119:1533-1540.
27. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., Imaizumi T. Endogenous nitric oxide synthase inhibitor. A novel marker for atherosclerosis. Circulation 1999, 99:1141-1146.
28. Nel A., Harvey B.H. Haloperidol-induced dyskinesia associated with striatal NO synthase inhibition: reversal with olanzapine. Behavioural Pharmacology 2003, 14:251-255.
29. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry 1991, 36:239-245.
30. Ozkurkcugil A., Aydemir O., Yildiz M., Danaci A.E., Koroglu E. DSM-IV eksen I bozukluklari icin yapilandirilmis klinik gorusmenin Turkceye uyarlanmasi ve guvenilirlik calismasi. Ilac ve Tedavi Dergisi. 1999, 12:233-236.
31. Prast H., Philippu A. Nitric oxide as modulator of neuronal function. Progress in Neurobiology 2001, 64:51-68.
32. Selley M.L. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Journal of Affective Disorders 2004, 80:249-256.
33. Soykan, C., 1989. Institutional differences, and case typicality as related to diagnosis system severity, prognosis and treatment. Yayimlanmamiş Yuksek Lisans Tezi. Ortadogu Teknik Universitesi. Ankara.
34. Stefano G.B. Biomedical Significance of Nitric Oxide 2003, Medical Science International Co. Ltd, Warsaw-New York.
35. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., Reaven G.M., Tsao P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Journal of the American Medical Association 2002, 287:1420-1426.
36. Valkonen V.P., Päivä H., Salonen J.T., Lakka T.A., Lehtimäki T., Laakso J., Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358:2127-2128.
37. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
38. Vita A., Bressi S., Perani D., Invernizzi G., Giobbio G.M., Dieci M., Garbarini M., Del Sole A., Fazio F. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. The American Journal of Psychiatry 1995, 152:876-882.